Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
T Cell Response
100%
Anti-PD-1 Therapy
100%
Melanoma
100%
B7-H1
100%
Programmed Death-ligand 1 (PD-L1)
37%
Programmed Cell Death Protein 1 (PD-1)
37%
Tumor
37%
Pembrolizumab
25%
Signaling Molecules
25%
Anti-PD-1 Blockade
25%
PD-1+ T Cells
25%
Metastatic Melanoma
25%
Downstream Signaling
25%
Clinical Trials
12%
Cancer Treatment
12%
Monitoring Biomarker
12%
Resistance Mechanism
12%
Therapeutic Target
12%
Pseudoprogression
12%
Anti-programmed Cell Death Protein 1 (anti-PD-1)
12%
Long-term Benefit
12%
Unselected Patients
12%
Therapeutic Response
12%
Anti-PD-1 Agents
12%
Radiologic
12%
Malignancy
12%
Prognostic Biomarker
12%
Treatment Outcome Prediction
12%
Therapeutic Efficacy
12%
Patient Demographics
12%
Treatment Application
12%
FDA-approved Drugs
12%
Treatment Resistance
12%
Personalized Approach
12%
Antitumor
12%
CD11a
12%
Anti-PD-1 Monoclonal Antibody
12%
Clinical Benefit
12%
Specific Aims
12%
Disease Status
12%
Pro-apoptotic
12%
Drug Efficacy
12%
New Drug Targets
12%
Variability in Response
12%
Immunotherapeutics
12%
Beta-blockers
12%
Disease Monitoring
12%
CD8+
12%
Peripheral Blood T Cells
12%
BH3-only Proteins
12%
PD-L
12%
Medicine and Dentistry
T-Cell Response
100%
Neoplasm
100%
Melanoma
100%
T Cell
75%
Pembrolizumab
75%
Programmed Death-Ligand 1
75%
Biological Marker
50%
Signaling Molecule
50%
Cancer
50%
Metastatic Melanoma
50%
Therapeutic Target
50%
Diseases
50%
Treatment Outcome
25%
CD8 Antigen
25%
Cancer Therapy
25%
Upregulation
25%
Patient Population
25%
Treatment Response
25%
BH3 Protein
25%
Immunomodulating Agent
25%
Drug Efficacy
25%
Monoclonal Antibody
25%
Clinical Trial
25%
Pharmacology, Toxicology and Pharmaceutical Science
Melanoma
100%
Neoplasm
100%
Pembrolizumab
75%
Metastatic Melanoma
50%
Biological Marker
50%
Diseases
50%
Clinical Trial
25%
CD8 Antigen
25%
Immunomodulating Agent
25%
Monoclonal Antibody
25%
BH3 Protein
25%
Malignant Neoplasm
25%